Serotonin and depression - a riposte to Moncrieff et al. (2022).
Level 5 - mechanism / opinion, no new human data
Narrative commentary and expert opinion without original empirical data or systematic review methodology.
What was done
The authors wrote a narrative commentary responding to a 2022 systematic umbrella review by Moncrieff and colleagues concerning the serotonin hypothesis of depression. The paper outlines theoretical frameworks and previously published literature on neurochemical heterogeneity, depletion studies, and neurotransmitter systems (serotonin, dopamine, noradrenaline, acetylcholine, glutamate, GABA, and neuroinflammation) in depression subtypes.
What was found
The abstract reports no empirical data, sample sizes, or statistical metrics. The authors state that the classic single-cause serotonin hypothesis has been considered outdated for decades and argue that decreased central serotonin activity characterizes a specific depressive subgroup (marked by negative affect, anxiety, insomnia, agitation, and suicidality) responsive to SSRIs, whereas catecholamine dysfunction characterizes another subgroup (marked by anhedonia and anergia) responsive to SNRIs.
Why it matters
This commentary provides insight into clinical psychopharmacology perspectives that view depression as neurobiologically heterogeneous rather than a uniform single-neurotransmitter deficiency.
Limits
This is an unsystematic narrative opinion piece without original patient data, quantitative meta-analyses, or documented search methods. The proposed subtype-specific mechanisms represent theoretical models and clinical commentary rather than newly tested findings.
Cited by
- supports Serious neuroscientists do not agree with or support the serotonin deficiency model of depression.